Two Phase III US studies (NX02-0017 and NX02-0018) of NX 1207, from Nymox Pharmaceutical, for the treatment of Benign Prostate...
Recordati and Nymox Pharmaceutical Corporation announced the start of activities aimed to the preparation of a European Phase III clinical...
Nymox Pharmaceutical reported top-line 5-year results from Nymox's U.S. Study NX03-0040 of NX 1207 (fexapotide triflutate) in prostate cancer.
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a...
Nymox Pharmaceutical Corp has announced major progress in the evidence for the safety and efficacy of NX 1207 (fexapotide), the...
Nymox Pharmaceutical has released data supporting the positive safety profile of NX 1207, for prostate enlargement (BPH or Benign Prostate...
AbbVie Inc. and Landos Biopharma, Inc. announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
Nymox Pharmaceutical Corp announced that the Company's U.S. long-term extension prospective double-blind Phase III BPH studies NX02-0017 and NX02-0018 of...
Braeburn Pharma announced that the FDA has granted tentative approval of Brixadi (buprenorphine fluidcrystal injection) extended-release weekly (8mg, 16mg, 24mg,...
Braeburn announces that the FDA has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product